A Phase IIb Randomized, Placebo-controlled, Double-blind Trial of Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants

Trial Profile

A Phase IIb Randomized, Placebo-controlled, Double-blind Trial of Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Azithromycin (Primary)
  • Indications Bacterial infections; Respiratory tract infections; Ureaplasma infections
  • Focus Therapeutic Use
  • Acronyms AZIPIII
  • Most Recent Events

    • 23 Jun 2017 Planned End Date changed from 1 Dec 2021 to 1 Dec 2019.
    • 23 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 02 Jun 2015 Planned End Date changed from 1 Dec 2016 to 1 Dec 2021 as reported in ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top